ClinicalTrials.Veeva

Menu

Testing Spectrosense EVA System for Detection of Pancreatic Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air

R

Rauscher, Gregory E., M.D. PA

Status

Unknown

Conditions

Pancreatic Cancer

Study type

Observational

Funder types

Industry

Identifiers

NCT01994681
00004108

Details and patient eligibility

About

Volatile Organic Compounds (VOC) in human breath are captured and analyzed by the Spectrosense EVA system, which is combination of a gas chromatography (GC) and software algorithm. The objective is to obtain a set or sets of VOC bio-markers that will provide the best discrimination between Pancreatic Cancer sick population and healthy population. The gold standard for identifying sick/healthy population is biopsy proven Pancreatic cancer.

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Pancreatic cancer Group

Inclusion Criteria:

  • Age from 18 years old
  • Pancreatic cancer positive biopsy
  • Before any treatment
  • Signed Informed Patient Consent

Exclusion Criteria:

  • Age under 18 years old
  • Neoadjovant treatment
  • Post surgery for Pancreatic cancer
  • A history of any other cancer type, except skin cancer that is not melanoma

Healthy Group

Inclusion Criteria:

  • Healthy patients
  • No history of Pancreatic cancer
  • Signed Informed Patient Consent

Exclusion Criteria:

  • History of Pancreatic cancer
  • Pancreatic cancer background in the family
  • A history of any other cancer type, except skin cancer that is not melanoma

Trial design

100 participants in 2 patient groups

Pancreatic Cancer
Healthy

Trial contacts and locations

1

Loading...

Central trial contact

Kevin Barga

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems